ストックスクリーナーアプリを入手
0.2526
2.27%
0.0056
アフターアワーズ：
.26
0.0074
+2.93%
前日終値:
$0.247
開ける：
$0.2525
24時間の取引高:
3.04M
Relative Volume:
3.19
時価総額：
$13.75M
収益：
$65.27M
当期純損益:
$-19.15M
株価収益率:
-0.4069
EPS:
-0.6208
ネットキャッシュフロー:
$-12.43M
1週間 パフォーマンス:
+0.04%
1か月 パフォーマンス:
-33.46%
6か月 パフォーマンス:
-55.12%
1年 パフォーマンス:
-43.11%
1日の値動き範囲:
$0.251
$0.279
1週間の範囲:
$0.2468
$0.2937
52週間の値動き範囲:
$0.2464
$1.32
Cosmos Health Inc Stock (COSM) Company Profile
名前
Cosmos Health Inc
セクター
電話
312-536-3102
住所
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM vs MCK, COR, CAH, HSIC, AHG
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COSM
Cosmos Health Inc
|
0.2526 | 13.44M | 65.27M | -19.15M | -12.43M | -0.6208 |
MCK
Mckesson Corp
|
734.82 | 89.24B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
264.69 | 52.41B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
195.15 | 46.09B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
76.40 | 8.72B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
1.49 | 1.30B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cosmos Health Inc (COSM) 最新ニュース
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Cosmos Health enters animal health market with C-Scrub brand - Proactive financial news
Cosmos Health extends C-Scrub brand into veterinary market - Investing.com
Cosmos Health enters $69B animal health market with C-Scrub Wash 4% after passing EU veterinary tests - Pluang
Cosmos Health Inc. Expands C-Scrub Brand into Veterinary Market with C-Scrub Wash 4% Launch - Quiver Quantitative
Cosmos Health Company Profile & Introduction - Moomoo
COSM: Cosmos Health Projects Strong Revenue Growth through 2029 - GuruFocus
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenu - The National Law Review
Cosmos Health (COSM) Forecasts FY26 Revenue Exceeding $90 Millio - GuruFocus
Cosmos Health Forecasts $200 Million Revenue by 2029 - geneonline.com
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation - Koreabizwire
Cosmos Health projects revenue to reach $200.6M by 2029 - Investing.com
Cosmos Health Releases 2026-2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation - The Manila Times
Cosmos Health targets $200 mln revenue, $44 mln adjusted EBITDA by 2029 - marketscreener.com
Cosmos Health Targets $200 Mln Revenue, $44 Mln Adjusted EBITDA By 2029 - TradingView
From $19M loss to $31M profit: Cosmos Health maps 2029 turnaround - Stock Titan
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash G - StreetInsider
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M - GlobeNewswire
Cosmos Health (COSM) Q1 2026: Revenue $17.93M Misses $21.67M Est - GuruFocus
Cosmos Health (NASDAQ: COSM) seeks shareholder votes on equity plan, Series B preferred - Stock Titan
Cosmos Health Q1 2026 Results: Record $17.9M Revenue, Liabilities Down, U.S. Expansion Underway - Minichart
Cosmos Health reports Q1 revenue up 31% to $17.9M; liabilities down $4.5M - TradingView
Cosmos Health (COSM) Q1 revenue up 31% as net loss widens - Stock Titan
Cosmos Health Reports Strong Q1 Results with Record Revenue - GuruFocus
Cosmos Health (COSM) Reports Strong Q1 2026 Revenue Growth - GuruFocus
Cosmos Health’s Series B warrants expire unexercised By Investing.com - Investing.com Nigeria
Cosmos Health’s Series B warrants expire unexercised - Investing.com
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants - ACCESS Newswire
4.87M Cosmos Health warrants expire with no new shares issued - Stock Titan
Cosmos Health reports Q1 revenue of $17.9M, up 31% year-over-year By Investing.com - Investing.com South Africa
Cosmos Health reports Q1 revenue of $17.9M, up 31% year-over-year - Investing.com Australia
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway - ACCESS Newswire
BRIEF-Cosmos Health Q1 Revenue USD 17.9 Million - TradingView
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues Into Q2 With U.S. Expansion Underway - 富途牛牛
COSM Shows Rapid Revenue Rise - Yahoo Finance
Cosmos Health Inc. 1Q 2026: Revenue $17.93M, EPS ($0.06) — 10-Q Summary - TradingView
Cosmos Health (NASDAQ: COSM) posts Q1 loss and issues going‑concern warning - Stock Titan
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt P - ACCESS Newswire
COSM Q1'26 Earnings: EPS estimate is (0.01) USD - TradingView
Cosmos Health Inc stock (US22143K1016): volatility after reverse split and uplisting plans draw inve - AD HOC NEWS
Cosmos Health Inc.Common Stock (NQ: COSM - FinancialContent
[NT 10-Q] Cosmos Health Inc. SEC Filing - Stock Titan
Cosmos Health (COSM) Engages European Investment Bank for R&D Fi - GuruFocus
Cosmos Health stock (US22143K1016): Pursues €25M EIB financing for R&D - AD HOC NEWS
Cosmos Health pursues €25M EIB financing for R&D program By Investing.com - Investing.com South Africa
Cosmos Health pursues €25M EIB financing for R&D program - Investing.com
Cosmos Health regains compliance with Nasdaq’s listing rule - MSN
Cosmos Health Inc (COSM) 財務データ
収益
当期純利益
現金流量
EPS
4.74%
2.60%
大文字化:
|
ボリューム (24 時間):